Understanding the Treatment Principles for Managing ADHD

Understanding the Treatment Principles for Managing ADHD

In this episode, Dr. Ferghal Armstrong and guest Dr. Manu Bhatnagar explore the treatment principles underlying the management of ADHD. If you want to gain valuable insights into the use of stimulant medication and non-stimulant pharmacology in addressing ADHD, this episode is a must-listen.

The focus keyword for this episode is "ADHD management." Dr. Armstrong and Dr. Bhatnagar provide in-depth analysis of the use of stimulant medications, such as dexamphetamine and lisdexamfetamine, as well as non-stimulant medications like atomoxetine, in the treatment of ADHD. They shed light on the difference between dexamphetamine and amphetamine, the safety concerns associated with stimulant therapy, and the role of non-stimulant pharmacology in ADHD management.

Learning outcomes:

1. Understanding the nuances of stimulant medications: Dr. Armstrong and Dr. Bhatnagar explain the mechanism of action and differences between amphetamines, including dexamphetamine, lisdexamfetamine, and methylphenidate, helping listeners grasp the key factors to consider when prescribing and using these medications.

2. Safety considerations and risk management: The episode delves into the potential risks associated with stimulant therapy, such as psychosis and substance use disorder, while also addressing the assessment and management of these risks to ensure safe and effective treatment for individuals with ADHD.

3. Exploring non-stimulant pharmacology: Listeners will gain insights into the role of atomoxetine as a non-stimulant medication for ADHD management. The episode highlights the considerations and scenarios where non-stimulant pharmacology might be preferred or necessary, providing a comprehensive view of treatment options.

Actionable takeaways:

1. Informed decision-making: Gain an understanding of the specific characteristics of different stimulant medications and how they impact dopamine release, enabling more informed decisions when prescribing medications for ADHD management.

2. Risk assessment and mitigation: Learn about the potential risks, such as psychosis and substance use disorder, associated with stimulant therapy, and discover strategies for assessing and managing these risks to ensure patient safety and treatment effectiveness.

3. Consideration of non-stimulant options: Explore the role of non-stimulant pharmacology, particularly atomoxetine, in the management of ADHD, and understand the scenarios where non-stimulant medications may be beneficial, providing a holistic approach to treatment.

Quote or insight:

"Every now and then, if you have that propensity to have a psychotic episode, [stimulant medication] might be the thing that adds another notch to your likelihood meter."

#ADHDmanagement #StimulantMedication #NonStimulantPharmacology #PatientSafety #RiskAssessment #Atomoxetine #InformedPrescribing #SubstanceUseDisorder #PsychosisRisk #CrackingAddiction

Thank you for tuning in to this episode of Cracking Addiction. For more insightful content, be sure to like and subscribe to our channel. You can find more information and episodes on our Meducate website: https://meducate.com.au.

Avsnitt(218)

LAIB - Sublocade

LAIB - Sublocade

Cracking Addiction discusses Sublocade one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Sublocade.Sublocade is a long acting injectable buprenorphine (LAIB) manufactured by Invidior that uses the “Atrigel” system to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.Discussions and comments in our videos are for informational purposes only and should not replace the advice of your medical professional. Please consult with your doctor before making any changes to your medical treatment or lifestyle.Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses available https://www.meducate.com.au

9 Feb 202215min

LAIB - Buvidal

LAIB - Buvidal

Cracking Addiction discusses Buvidal one of the LAIB preparations available and how to commence, maintain and manage any dose changes or complications associated with Buvidal.Buvidal is a long acting injectable buprenorphine (LAIB) preparation manufactured by Camurus and uses “FluidCrystal” technology to provide for a sustained and prolonged delivery of buprenorphine into the systemic circulation after subcutaneous injection.

3 Feb 202217min

LAIB  Special Circumstances

LAIB Special Circumstances

Cracking Addiction discusses some of the special or difficult circumstances of prescribing LAIBs including intoxicated patients, pregnant patients, patients with chronic disease, patients with acute pain and our management strategies in these situations.

26 Jan 202219min

LAIB first dose considerations

LAIB first dose considerations

Episode 23 of Cracking Addiction explores commencement of patients on LAIB, side effects and risks of LAIB, discussion about precipitated withdrawal and when and how to review patients

20 Jan 202220min

Long Acting Injectable Buprenorphine (LAIB) - Introduction

Long Acting Injectable Buprenorphine (LAIB) - Introduction

An Introduction to Long Acting Injectable Buprenorphine (LAIB)Long acting injectable buprenorphine (LAIB) are long acting buprenorphine depot preparations that are injected subcutaneously and provide patients with a sustained release of buprenorphine for the duration of the depot preparation. Currently, two LAIB products are available for the Australian market. They differ in their formulations, administration and pharmacology.See blog for further informationhttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

12 Jan 202218min

Methadone pharmacokinetics and interactions

Methadone pharmacokinetics and interactions

Episode 21 of Cracking Addiction explores methadone pharmacokinetics, breakdown and interactions within the body and interactions with other drugs.Methadone is a drug with a wide variability in its absorption with oral bio-availability ranges from 35% to 100%. This is a significant amount of variability and explains why the same dose of Methadone can impact different patients differently. Methadone is metabolised within the liver by the cytochrome P450 enzymes but mainly 3A4. There is a 17-fold inter-individual variation of methadone blood concentration for a given dosage and variations in metabolism account for a large part of this variation. Kinetic interactions influenced by the CYP 450 enzyme can affect plasma methadone levels.• Inducers of CYP450 can• Accelerate the metabolism of methadone• lower methadone plasma levels• Precipitate opioid withdrawal • Inhibitors of CYP450 can • Slow the metabolism of methadone• Increase plasma levels• Produce opioid toxicity (sedation, overdose)Methadone is excreted renally with approximately 10% of drug renally eliminated unchanged. Renal excretion of methadone urinary pH dependent with increased Methadone excretion noted at pH less than 6 and decreased Methadone excretion at higher pH levels.About Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

22 Dec 202116min

Methadone pharmacology and induction

Methadone pharmacology and induction

Episode 20 of Cracking Addiction explores methadone, its origins, the pharmacology behind methadone and how to commence a patient on Methadone.Methadone is a synthetic long acting mu receptor agonist suitable for the treatment of opioid use disorder. Methadone has a longer plasma half life than morphine (average 22 hours (15-32 hours) vs 2 hours for morphine) which permits once daily supervised dosing.https://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

15 Dec 202122min

Opioid use disorder Post Partum

Opioid use disorder Post Partum

Episode 19 of Cracking Addiction explores the management of opioid use disorder in the post partum period.Post birth the patient's usual oral methadone dose can be continued in the peripartum and post partum period. There is a theoretical concern in the postpartum period of over-sedation as methadone levels may increase as plasma volume and hepatic clearance normalise post the delivery of the child. Latest Blogshttps://www.meducate.com.au/blogAbout Meducate ®Meducate provides online education for doctors, clinicians, health professionals and the public.See the website to browse the many different talks and courses availablehttps://www.meducate.com.au

9 Dec 202111min

Populärt inom Hälsa

rss-bara-en-till-om-missbruk-medberoende-2
somna-med-henrik
alska-oss
inga-beiga-morsor
johannes-hansen-podcast
sexnoveller-deluxe
angestpodden
rss-viktmedicinpodden
sova-med-dan-horning
rss-the-house-podcast-3
rss-sjalsligt-avkladd
giggles-med-wiggles
not-fanny-anymore
rss-the-house-podcast-4
sa-in-i-sjalen
sag-det-bara
brottarbroder
medicinvetarna
rss-sexmorgon
tyngre-radio